We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Andrx Loses Appeals Case To Market Generic Biaxin XL
Andrx Loses Appeals Case To Market Generic Biaxin XL
January 23, 2007
A federal court has upheld a preliminary injunction preventing Watson subsidiary Andrx Pharmaceuticals from marketing clarithromycin, a generic version of Abbott Laboratories’ extended-release antibiotic Biaxin XL.